1. Home
  2. TBPH vs CRF Comparison

TBPH vs CRF Comparison

Compare TBPH & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$19.87

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Cornerstone Total Return Fund Inc. (The)

CRF

Cornerstone Total Return Fund Inc. (The)

HOLD

Current Price

$7.93

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
CRF
Founded
2013
1973
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TBPH
CRF
Price
$19.87
$7.93
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$27.80
N/A
AVG Volume (30 Days)
376.6K
1.1M
Earning Date
02-25-2026
01-01-0001
Dividend Yield
N/A
18.10%
EPS Growth
N/A
N/A
EPS
0.58
1.40
Revenue
$80,327,000.00
$11,461,786.00
Revenue This Year
$70.78
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.64
$5.38
Revenue Growth
27.12
6.53
52 Week Low
$7.90
$5.70
52 Week High
$21.03
$9.56

Technical Indicators

Market Signals
Indicator
TBPH
CRF
Relative Strength Index (RSI) 54.78 43.90
Support Level $18.78 $7.84
Resistance Level $21.03 $8.00
Average True Range (ATR) 0.81 0.06
MACD -0.15 -0.01
Stochastic Oscillator 45.60 26.56

Price Performance

Historical Comparison
TBPH
CRF

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.

Share on Social Networks: